Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
about
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsTarget of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsMammalian target of rapamycin inhibitors for heart transplant patientsTarget of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsConversion of calcineurin inhibitor treatment to target of rapamycin inhibitor treatment versus continuation of calcineurin inhibitor treatment for liver transplant recipientsMammalian target of rapamycin inhibitors for heart transplant patientsAntiviral drug resistance: mechanisms and clinical implicationsAu-ACRAMTU-PEt3 Alters Redox Balance To Inhibit T Cell Proliferation and FunctionLong-term cancer risk of immunosuppressive regimens after kidney transplantation.Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysisImmunosuppressive drug therapy.Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis.Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
P2860
Q24187213-6E7B6ACA-BCC5-450F-80DB-48B1B03976C2Q24187866-E7A87135-4E01-4C33-9DFE-8D2DB914CC6AQ24194002-E1AE9A0A-C38D-46DB-9374-577C4772ED60Q24201591-BD471CFA-E2FE-41D6-A4EE-D62A4FB8CE45Q24234041-7544F6BD-C28D-45FE-A760-C3EF2DA880F0Q26470671-577E3BE5-C7B1-45CE-8211-C020C7CC500BQ28282376-C42CF67B-BDC2-4D7F-A623-41D8D2D16564Q28393579-AC9ED8A3-E540-4157-B524-1CC5D025E1AFQ33834315-C7CF12FA-D1EE-4F24-A87A-213CC6C77B5BQ35900978-FB57AD69-8992-4371-A3BF-C174C731388DQ38134066-1379E425-2306-445C-849D-2CF35CE201D3Q43038395-9C48A8F8-730F-4E77-8B88-510A9EF460B5Q57151742-588F8CE6-9D35-4B1A-87C5-12933523F363
P2860
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Target of rapamycin inhibitors ...... n kidney transplant recipients
@ast
Target of rapamycin inhibitors ...... n kidney transplant recipients
@en
Target of rapamycin inhibitors ...... n kidney transplant recipients
@en-gb
Target of rapamycin inhibitors ...... n kidney transplant recipients
@nl
type
label
Target of rapamycin inhibitors ...... n kidney transplant recipients
@ast
Target of rapamycin inhibitors ...... n kidney transplant recipients
@en
Target of rapamycin inhibitors ...... n kidney transplant recipients
@en-gb
Target of rapamycin inhibitors ...... n kidney transplant recipients
@nl
prefLabel
Target of rapamycin inhibitors ...... n kidney transplant recipients
@ast
Target of rapamycin inhibitors ...... n kidney transplant recipients
@en
Target of rapamycin inhibitors ...... n kidney transplant recipients
@en-gb
Target of rapamycin inhibitors ...... n kidney transplant recipients
@nl
P2093
P2860
P1476
Target of rapamycin inhibitors ...... n kidney transplant recipients
@en
P2093
Angela C Webster
Jeremy R Chapman
Vincent WS Lee
P2860
P356
10.1002/14651858.CD004290.PUB2
P577
2006-04-19T00:00:00Z